PetrosGeorgeNikolinakosMD

Hematologic Oncology

Adjunct Associate Professor UGA, Director of Clinical Research, Managing Partner Hematology and Medical Oncology, University Cancer & Blood Center, LLC

Join to view full profile

Dr. Nikolinakos is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Nikolinakos' full profile

Already have an account?

Office
3320 Old Jefferson Rd
Bldg 800
Athens, GA 30607
Phone+1 706-353-2990

Fax+1 706-353-2992

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
Cook County Health and Hospitals SystemChief Residency, Internal Medicine, 2001 - 2002
Cook County Health and Hospitals SystemResidency, Internal Medicine, 1998 - 2001
University of Debrecen Medical and Health Science CenterClass of 1996

Certifications & Licensure

GA State Medical License 2009 - 2026
TX State Medical License 2007 - 2023
IL State Medical License 1998 - 2002
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Clinical Trials Participation Award Conquer Cancer Foundation of ASCO, 2013

Clinical Trials

PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score Start of enrollment: 2012 May 01
Completed
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi Start of enrollment: 2012 Oct 03
Terminated
Phase 3
Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta) Start of enrollment: 2012 Dec 11
Terminated
Phase 3
Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib Start of enrollment: 2013 Aug 01
Completed
Phase 2
BKM120 for Patients With PI3K-activated Tumors Start of enrollment: 2013 Mar 29
Completed
Phase 2
Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2013 Oct 14
Completed
Phase 2
Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL) Start of enrollment: 2013 May 01
Completed
Phase 1
MEK162 for Patients With RAS/RAF/MEK Activated Tumors Start of enrollment: 2013 Oct 10
Completed
Phase 2
A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants Start of enrollment: 2013 Aug 01
Completed
Phase 2
Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma Start of enrollment: 2013 Sep 16
Active, not recruiting
Phase 3
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors Start of enrollment: 2014 Mar 01
Completed
Phase 1, Phase 2
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer Start of enrollment: 2014 Jul 22
Active, not recruiting
Phase 3
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer Start of enrollment: 2014 Oct 03
Active, not recruiting
Phase 3
Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE) Start of enrollment: 2015 May 01
Completed
Phase 3
A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer Start of enrollment: 2015 Aug 01
Completed
Phase 2
Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy Start of enrollment: 2015 Oct 05
Terminated
Phase 1, Phase 2
MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors Start of enrollment: 2015 Aug 31
Completed
Phase 1
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Start of enrollment: 2015 Nov 19
Active, not recruiting
Phase 2
A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks Start of enrollment: 2016 May 24
Completed
Phase 3
eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients Start of enrollment: 2016 Jun 01
Active, not recruiting
Phase 3
Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2016 Aug 01
Terminated
Phase 1, Phase 2
Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer Start of enrollment: 2017 Feb 22
Completed
Phase 2
Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer Start of enrollment: 2017 Mar 24
Active, not recruiting
Phase 3
Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC) Start of enrollment: 2017 May 01
Completed
Phase 2
A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney Start of enrollment: 2017 Jul 07
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

515 citations
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.
Luc Dirix, István Takács, Guy Jerusalem, Petros Nikolinakos, Hendrik Tobias Arkenau
Breast Cancer Research and Treatment. 2018-10-23
39 citations
Atypical Chemokine Receptor 1 (DARC/ACKR1) in Breast Tumors Is Associated with Survival, Circulating Chemokines, Tumor-Infiltrating Immune Cells, and African Ancestry
Brittany D. Jenkins, Rachel Martini, Rupali Hire, Andrea Brown, Briana Bennett
Cancer Epidemiology, Biomarkers & Prevention. 2019-04-01
507 citations
Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA
Richard B. Lanman, Stefanie Mortimer, Oliver A. Zill, Dragan Sebisanovic, Rene Lopez
Plos One. 2015-10-16

Journal Articles

A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously expos...
Ahmed Sawas, Charles M. Farber, Marshall T. Schreeder, Mazen Y. Khalil, Daruka Mahadevan, Changchun Deng, Jennifer E. Amengual, Petros G. Nikolinakos, Jill M. Kolesar,..., Br J Haematol, 1/1/2017
PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Permetrexed versus Paclitaxel + Carboplatin + Bevaciz...
Ralph G. Zinner, MD, Coleman K. Obasaju, MD, PhD, David R. Spigel, MD, Robert W. Weaver, MD, J. Thaddeus Beck, MD, David M. Waterhouse, MD, MPH, Manuel R. Modiano, MD,..., J Thorac Oncol, 1/1/2015
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy ...
Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Van Cutsem E, Grothey A, Prausova J, Garcia-Alfonso P, Yamazaki ..., Lancel Oncol, 1/1/2015
Two Genomic Strategies in Non-Small Cell Lung Cancer Prognosis
Nikolinakos P, Lippman SM, Abstracts in Hematology and Oncology, 1/1/2007
Photo Quiz Back Rash
Shekarappy RJ, Nikolinakos P, Bansidhar T, Sistoza E, Smith J, Am Fam Physician, 1/1/1999
Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell Free Circulating Tumor DNA
Richard B. Lanman, Stefanie A. Mortimer, Oliver A. Zill, Dragan Sebisanovic, Rene Lopez, Sibel Blau, Eric A. Collisson, Stephen G. Divers, Dave S.B. Hoon, E. Scott Kop..., PLOS ONE, 1/16/2015
High Pathologic Complete Response in HER2-Positive, Early-Stage Breast Cancer to a Novel Non-Anthracycline Neoadjuvant Chemotherapy
Amelia Zelnak, Petros Nikolinakos, Jayanthis Srinivasiah, William Jones, Andrew Pippas, Yuan Liu, Xiaoxian Li, Mylin Torres, Ruth M. O'Regan, Clinical Breast Cancer
Epiderman Growth Factor Receptor Regulated MET Levels and Invasiveness Through Hypoxia-Inducible Factor-1alpha in Non-Small Cell Lung Cancer Cells
Xu L, Nilsson MB, Saintignv P, Cascone T, Herynk MH, DU Z, Nikolinakos PG, Yang Y, Prudkin L, Liu D, Lee JJ, Johnson FM, Wong KK, Girard L, Gazdar AF, Minna JD, Kurie ..., Oncogene, 1/15/2010
Join now to see all

Abstracts/Posters

Emergence of RET Rearrangement Co-Existing with Activated EGFR Mutation in EGFR-Mutated NSCLC Patients Who Had Progressed on First- or Second-Generation EGFR TKI
Klempner SJ, Bazhenova LA, Braiteh FS, Nikolinakos PG, Gowen K, Cervantes CM, Chmielecki J, Greenbowe JR, Ross JS, Stephens PJ, Miller VA, Ali SM, Ou SH, 1/1/2015
Phase I/II Study of Neoadjuvant Carboplatin, Eribulin Mesylate and Trastuzumab (ECH) for Operable HER2 Positive (HER2+) Breast Cancer
Lee S. Schwartzberg, MD; Kurt W. Tauer, MD; Robert C. Hermann, MD; Petros G. Nikolinakos, MD; Arthur C. Houts, PhD, J Clin Oncol, 1/1/2013
Reverse-Phase Protein Array (RPPA) Profiling of Response to Taxanes and Epidermal Growth Factor Receptor (EGFR) Inhibitors Identifies an Inverse Correlation Between Ma...
Lauren Averett Byers, Meera Nanjundan, Luc Girard, Kevin Coombes, Yang Xie, Michael Peyton, Sunny Zachariah, Stephanie Weber, Doris Siwak, Petros Nikolinakos, Gordon M..., AACR Meeting, 1/1/2008
Differential Regulation Hypoxia Inducible Factor (HIF)-1alpha and -2alpha in Human NSCLC Cell Lines Bearing Wild Type and Mutated EGFR
Tina Cascone, Petros Nikolinakos, Li Xu, Matthew Herynk, Monique Nilsson, and John Heymach, AACR Meeting, 1/1/2008
Analyses of Plasma Cytokine/Angiogenic Factors (C/AFs) Profile During Preoperative Treatment with Pazopanib (GW786034) in Early-Stage Non-Small Cell Lung Cancer
Petros Nikolinakos, N. Altorki, M. Guarino, H. Tran, D. Rajagopalan, S. Swann, W. Bordogna, L. Ottesen, D. Yankelevitz, J.V. Heymach, J Clin Oncol, ASCO, 1/1/2008
Reverse-Phase Protein Array (RPPA) Profile of Non-Small Cell Lung Cancer Lines Identifies Tumor Signatures for Sensitivity and Resistance to Chemotherapy and Targeted ...
Byers, Lauren Averett, Nanjundan, Meera, Girard, Luc, Coombes, Kevin, Xie, Yang, Peyton, Michael, Ma, Yao, Zachariah, Sunny, Nikolinakos, Petros, Minna, John, Heymach,..., AACR Meeting, 1/1/2007
Trilaciclib (GIT28), a Cyclin Dependent Kinase 4/6 Inhibitor, in Combination with Etoposide and Carboplatin (EP) for Extensive Stage Small Cell Lung Cancer (ES-SCLC): ...
Caio Max S, Rocha Lima, Patrick J. Roberts, Victor M. Priego, Stephen G. Divers, Melanie B. Thomas, Ralph V. Boccia, Katie Stabler, Elizabeth Andrews, Rajesh K. Malik,...
Safety Profile of Nivolumad Administered as 30-Minute (min) Infusion: Analysis of Data From CheckMate 153
David Michael Waterhouse, Leora Horn, Craig H. Reynolds, David R. Spigel, Jason Claud Chandler, Tarek Mekhail, Mohamed K. Mohamed, Ben C. Creelan, Kenneth Bruce Blanks...
Colorectal Cancer (CRC) Cohort Analysis of Patients Treated with Buparlisib in a Distinctive Tissue-Agnostic Trial Model for Molecularly Pre-Selected Tumors
Sarina Anne Piha-Paul, James A. Knost, Petros Nikolinakos, Lee Steven Schwartzberg, Denise A. Yardley, Eric Daniel Slosberg, Barinder Kang, Theresa White, Claudia Lebe...
Impact of Next-Generation Sequencing (NGS) on Treatment Decision in the Community Oncology Setting
Lindsay Carol Overton, Christopher L. Corless, Manish Agrawal, Vasily J. Assikis, Nancy L. Beegle, Sibel Blau, Marc Chernoff, Stephen G. Divers, David H. Henry, Petros...
Results of a Phase I Dose-Escalation Trial with Ublituximab (TG-1101), a Novel Anti-CD20 Monoclonal Antibody (mAb) for Patients with Rituximab Relapsed/Refractory Lymp...
Owen A. O'Connor, MD, PhD, Changchun Deng, MD, PhD, Jennifer E. Amengual, MD, Marshall Schreeder, MD, Daruka Mahadevan, MD, Mazen Y. Khalil, MD, Petros Nikolinakos, MD...
Join now to see all

Press Mentions

University Cancer & Blood Center Covington Facility Moves to New LocationDecember 15th, 2022
University Cancer & Blood Center Hosts A Community Conversation: Living with Lung CancerJanuary 18th, 2016

Professional Memberships

American Society of Clinical Oncologists - ASCO
Member
American Society of Hematology - ASH
Member